Norlin JM, et al. - Because it is suggested that PASI90 be the new standard endpoint RCTs for psoriasis biologics, whereas treatment guidelines often still refer to PASI75, researchers analyzed the factors associated with higher levels of treatment response to biologics in a real-world setting and the gains in Health-Related Quality of Life associated with different levels of response in clinical practice. Biologically-naïve subjects with PASI, DLQI and EQ-5D outcomes before (maximum 6 months) and after (3-12 months) switch to biologics during registration in the Swedish Register for systemic treatment of psoriasis, PsoReg, were involved (n=515). By regression analyses, patient characteristics related to higher treatment response were analyzed. According to findings, PASI percentage change depends largely on absolute pre-switch PASI. Patients in clinical practice lack "baseline" PASI values since they can switch directly from one treatment to another or stay treated successfully for a longer period of time. Treatment objectives like PASI90 are therefore not appropriate for guidelines for therapy or for clinical practice follow-up.